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Current MRI (Magnetic Resonance Imaging) is based on the 
1H NMR relaxation of water and affords morphological images 
of the body.1 New directions of MRI focus on specific detection 
of tumors, which may be MR-imaged using either tumor targeters 
appropriately labeled with MR-responsible moieties such as 19F 
nuclei2 or paramagnetic contrast agents,3 or specific signal 
amplification techniques such as hyperpolarization4 and chemical 
exchange saturation transfer5 for tumor-responsible small 
molecules such as pyruvate, H2O2, or glucose. Recently, we 
reported a different approach.6 A phosphorylcholine polymer 
(PMPC) enriched with 13C at the methyl groups with a mean 
molecular weight of Mn = 63,000 was found to accumulate highly 
selectively and efficiently in the tumor (colon 26) of tumor-
bearing mice primarily by the so-called EPR (Enhanced 
Permeability and Retention) effect, and the tumor could be 
clearly MR-visualized with this 13C-concentrated polymeric 
nano-probe by the 1H–13C double-resonance7 (heteronuclear 
correlation) technique.6c This probe thus provides a novel
example of a self-traceable EPR polymer that is free from foreign 
labeling. However, there are still some issues that need to be 
addressed if this probe is to have wider applicability as a tumor 
imager. One issue is the slowness of accumulation and clearance. 
Another involves the general utility of the EPR effect8, i.e., the 
size-allowed invasion and retention of nano-particles in tumor 
tissues which usually have a defective vascular wall with a wide 
opening and undeveloped lymphatic drainage. Although the EPR 
effect has been widely used for the passive targeting of tumors,9 
the EPR-susceptibility of tumor tissues depends on the type of 
tumor.10 While colon 26, a mouse rectal cancer cell line, is highly 
susceptible to EPR, this is not necessarily true for other types of 
tumors.11 In the present work, we prepared a conjugate of 13C-
PMPC as an MR signal generator with an antibody fragment as 
an active tumor targeter, and investigated the performance of this 
conjugate with the above issues in mind. We report here that the 
antibody-functionalized probe can selectively image an antibody-






A 13C-enriched phosphorylcholine polymer (13C-PMPC) as a self-traceable MR (Magnetic 
Resonance) tag was conjugated with a fragment (scFv) of Herceptin, a clinical antibody against 
antigen Her2. When injected in model mice bearing Her2(+) (gastric) and Her2(–) (pancreatic) 
tumors, the antibody-tag conjugate 13C-PMPC-scFv selectively accumulated in the Her2(+) 
tumor with a rapid build-up/decay (accumulation/clearance) profile and, with the use of the 1H–
13C double-resonance (heteronuclear correlation) technique, the Her2(+) gastric tumor was 
clearly MR imaged. 
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Scheme 1. Preparation of 13C-PMPC-scFv. A, atom-transfer radical polymerization of monomer 13C-MPC to afford polymer 13C-PMPC 1a (Mn = 35,000). B, 
retro-Diels Alder reaction of protected polymer 1a to give deprotected one 13C-PMPC 1b with an active maleimide terminus. C, coupling of the maleimide of 1b 
with a fragment (scFv, M = ca. 27,000) of Herceptin to afford 13C-PMPC-scFv (Mn = 62,000). 
Figure 1. (a) GPC trace for 13C-PMPC-scFv. Retention times for scFv (M = 
27,000) and its S-S (disulfide) dimer (M = 54,000) (see Supplementary 
Information) are also indicated. (b) SDS-PAGE analysis for 13C-PMPC-scFv. 
Lane 1, molecular-weight marker. Lane 2, monomeric scFv (M = ca. 27 kDa). 
Lane 3, 13C-PMPC-scFv (M = 62 kDa). The broad band observed for 13C-
PMPC-scFv is due to molecular-weight distribution (Mw/Mn = 1.4) for the 
PMPC moiety. (c) One-dimensional 1H–{13C} double-resonance NMR 
spectrum for 13C-PMPC-scFv in D2O, showing a single signal for the 13C-
enriched methyl protons. The spectrum was obtained at 25 ºC with a Bruker 
Avance 700 spectrometer equipped with a 5 mm TCI CryoProbe in a similar 
manner as reported previously.6c (d) Ex vivo double-resonance NMR 
spectrum of the Her2(+) tissue removed from a probe-administered mouse at 
a time point of 48 h from injection of the probe. 
responsive but otherwise less EPR-susceptible tumor with a rapid 
build-up/decay profile. 
Methacryloyloxyethylphosphorylcholine (MPC) enriched with 
13C at the choline methyl groups was polymerized under the 
atom-transfer radical polymerization (ATRP) conditions12 using 
furan-protected maleimide bromide (R-Br) as an initiator and 
CuBr/2,2’-bipyridine as a catalyst, according to the scheme 
n(MPC) + R-Br  R-(MPC)n-Br (Scheme 1)6c. The polymer thus 
obtained (13C-PMPC) had a mean molecular weight of Mn = 
35,000 (n = 118) and a polydispersity index of Mw/Mn = 1.4. This 
was subjected to coupling with a fragment (scFv) of Herceptin, a 
well-known clinical antibody against antigen Her2 that is 
expressed in breast cancer as well as gastric cancer.13 The actual 
fragment used (scFv) was a 257-amino acid sequence (from M1 
to C257) that contained fragments of the heavy and light chains 
of Herceptin, conjugated with a nonapeptide (H6G2C) composed 
of a His-tag (H6) linked with a tripeptide glycine-glycine-cysteine 
(G2C) at the C-terminus (Supplementary Information for 
details).14 The genetically engineered single-chain fragment 
variable (scFv, M = ca. 27 kDa) was expressed in E. coli and 
purified by His-tag-targeted affinity chromatography. For 
polymer-antibody coupling, 13C-PMPC was carefully heated in 
vacuo at 105 ºC in the absence of any solvent to allow 
deprotection (retro-Diels Alder removal of the furan ring) of the 
terminal initiator moiety into an active maleimide form. Addition 
(Michael addition) of the terminal cysteine residue in scFv to the 
maleimide at a molar ratio of 13C-PMPC/scFv = 24.5 afforded 
conjugate 13C-PMPC-scFv with a mean molecular weight of 
35,000 + 27,000 = 62,000, which was freed from 13C-PMPC in 
excess on treatment with a His-tag column, purified by size-
exclusion chromatography (GPC) (Figure 1a), and characterized 
by electrophoresis (SDS-PAGE) (Figure 1b) and 1H-{13C} 
double-resonance NMR analysis (Figure 1c). 
Antigen Her2 is known to be highly expressed in gastric 
cancer as well as in breast cancer, but not in pancreatic cancer.15 
Thus, N87 (a human gastric cancer cell line) and SUIT2 (a 
human pancreatic cancer cell line) were used here as Her2(+) and 
Her2(–) tumor cells, respectively.16 Model mice were obtained by 
transplanting the Her2(+) and Her2(–) tumor cells at the right 
shoulder and the contralateral left shoulder, respectively, of 
healthy mice (~20 g). Probe 13C-PMPC-scFv (113.5 mg/kg = 
1.83 μmol/kg body weight or 2.27 mg/20-g mouse) was 
intravenously injected into the tail vein of tumor-bearing mice. In 
vivo MR images of the mice were taken under probe-optimized 
double-resonance (1H–{13C}) conditions in essentially the same 
manner as described elsewhere6c (Supplementary Information for 
details). Figure 2a shows a typical image (double-resonance 
image overlaid on a T2-weighted single-resonance (1H) 
morphological image)17 taken at 22 h after administration of the 
probe. We can clearly see that (1) the Her2(+) gastric tumor is 
clearly visualized while the Her2(–) pancreatic tumor is hardly 
visible, and (2) there is no appreciable accumulation of the probe 
in the liver, although some unidentified, noise-looking spots are 
still noticed. The observed Her2(+)/Her2(–) selectivity is 
probably a consequence of scFv-mediated active targeting of the 
Her2(+) tumor by the probe, since the reference probe 13C-PMPC 
(Mn = 35,000), which lacks in the antibody scFv moiety, shows 
no notable affinity for the Her2(+) tumor (Figure 2b). Figure 3 
shows a rough time course of imaging of the tumor sites at 4 h, 
22 h, and 46 h. The Her2(+) site exhibits a monotonous decrease 
in image intensity with signal-to-noise ratios of S/N = 12.9, 9.6, 
and 4.1 at 4 h, 22 h, and 46 h, respectively. The Her2(–) site is 
just barely imageable at 4 h, but then fades away in 1 day. Ex 
vivo measurements for the tumor sites removed from the probe-
administered mouse clearly show selective accumulation of the 
probe in the Her2(+) tumor (Figure 1d). Even at a time point of 
48 h from injection, the double-resonance signal of the probe in 
Her2(+) is twice as intense as that in Her2(–).18 
Figure 2. Probe-targeted double-resonance (1H–{13C}) MR images colored 
red by ImageJ software, overlaid on morphological images (T2-weighted 
single resonance). (a) Merged image for a tumor-bearing mouse bearing 
Her2(+) tumor (N87) at the right shoulder and Her2(–) tumor (SUIT2) at the 
contralateral left shoulder, at 22 h after the administration of 13C-PMPC-scFv 
(113.5 mg/kg = 1.83 μmol/kg body weight or 2.27 mg/20-g mouse). (b) 
Merged image for a similar mouse administered 13C-PMPC35,000 (64 mg/kg = 
1.83 μmol/kg body weight or 1.28 mg/20-g mouse). 
Figure 3. Time course of the change in merged images for the Her2(+) and 
Her2(–) tumor sites of a mouse administered probe 13C-PMPC-scFv as in 
Figure 2a. 
The present active tumor-targeting may be compared with 
previously reported passive EPR tumor-targeting. There is a 
striking difference in the build-up/decay profiles. It takes ~2 days 
for the antibody-free probe 13C-PMPC (Mn = 63,000) to settle in 
colon 26 tumor with a gradual increase in the S/N ratio, and the 
probe accumulated in the tumor is stably retained therein for at 
least a week without undergoing clearance.6c In marked contrast, 
uptake of the antibody-functionalized probe 13C-PMPC-scFv (Mn 
= 62,000) by the N87 tumor is rapid (<4 h), but the probe is 
cleared rather rapidly with a gradual decrease in the S/N ratio 
within ~2 days (Figure 3, top). On the other hand, the two probes 
share a common characteristic. As in the case of 13C-PMPC,6c 
there is no appreciable nonspecific binding of probe 13C-PMPC-
scFv to normal organs, especially the liver (Figure 2a), which is 
often a major deposition site of nano-probes and nano-
medicines.19 Formally, comparison of these two probes helps us 
to characterize the role of scFv. However, there is an obstacle. 
The two probes with similar molecular weights (62,000 vs 
63,000) are far from analogous to each other with respect to size. 
Probe 13C-PMPC, which is plausibly free from aggregation, 
forms compact particles with a mean dynamic light scattering 
(DLS) size of dDLS = 13.1 ± 0.13 nm for 13C-PMPC63,000 as 
reported previously6c or dDLS = 8.41 ± 0.05 nm for 13C-PMPC35,000 
(Figure 4b). In marked contrast, the antibody-functionalized 
probe 13C-PMPC-scFv62,000 is highly aggregated and forms large 
particles with dDLS = 175.3 ± 2.5 nm (Figure 4a). 
Size is an important factor that governs the pharmacokinetics 
of nano-particles. Roughly, EPR-relevant sizes are in the range of 
10–100 nm.20 Smaller (<10 nm) and larger (>100 nm) particles 
are susceptible to clearance, respectively, by renal excretion21 and 
the reticuloendothelial systems, particularly via phagocytosis by 
macrophages distributed in various organs such as liver.22 
Another factor to consider is biocompatibility. Phosphorylcholine 
comprises the head group of cell-membrane lipids 
(phosphatidylcholine), and polymers derived therefrom, 
including PMPC, are known to be biologically inert.23 They 
escape from phagocytosis, probably because they are not 
recognized as foreign bodies by macrophages.24 In this context, 
the biocompatibility of PMPC may primarily deactivate the 
macrophage/liver pathway for PMPC-based polymers regardless 
of their sizes. The rapid clearance of 13C-PMPC-scFv is more 
difficult to explain at present. The antibody fragment scFv 
conjugated with a long polymer chain (PMPC), possibly via 
electrostatic interaction between them, might be susceptible to 
hydrolytic degradation to lose its affinity for the Her2(+) N87 site, 
although this is by no means conclusive and further rigorous 
investigation will be required. 
Figure 4. DLS size distribution profiles for (a) 13C-PMPC-scFv (Mn = 
62,000) (2.3 mg/mL in PBS) and (b) 13C-PMPC (Mn = 35,000) (1 mg/mL in 
water). 
In this work, we investigated how 13C-PMPC performs as a 
self-traceable MR tag for a tumor-targeting antibody. The 
antibody-tag conjugate exhibited expected antigen(+)/antigen(–) 
selectivity and MR-imaged the antigen(+) tumor with a rapid 
build-up/decay or accumulation/clearance profile. The dose of 
the present probe (113.5 mg/kg = 1.83 μmol/kg) is comparable to 
(on a weight basis) or much lower (on a molar basis) than that of 
Magnevist (74 mg/kg = 0.1 mmol/kg), a clinical contrast agent 
  
that is widely used in current MRI. The detection limit of 
imaging of the present 13C-PMPC-scFv probe would be ~18 μM, 
25 which is slightly higher than the detection limit (several μM) 
reported for a gadolinium contrast agent.26 The use of synthetic 
polymers as a tag may offer both advantages and disadvantages 
compared with small optical tags such as fluorophores. Synthetic 
polymers are also widely and uniquely used as carriers of drugs 
and genes27 and as stabilizers of clinical protein and nucleic acid 
medications.28 In this context, this work may represent a step 
toward the visualization of various delivery/localization events 
mediated by synthetic polymers. At the same time, this work 
revealed an unexpected problem: aggregation-free PMPC 
becomes highly aggregated upon modification with scFv, which 
(dDLS = 10.3 nm) alone supposedly does not aggregate. 
Phosphorylcholine polymer (PMPC) is zwitterionic, i.e., it is an 
ammonium-phosphate polybetaine. The scFv moiety seems to 
perturb the otherwise intramolecular/intrastrand electrostatic 
interaction of PMPC29 and promote intermolecular/interstrand 
interaction thereof. Further work is now underway in our 
laboratories to gain deeper insight into the pharmacokinetics of 
the present and related PMPC probes and to shed more light on 
the effects of terminal substituents on the aggregation states of 
PMPC polymers. 
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